These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18176610)

  • 1. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation.
    Barkholt L; Remberger M; Hassan Z; Fransson K; Omazic B; Svahn BM; Karlsson H; Brune M; Hassan M; Mattsson J; Ringdén O
    Bone Marrow Transplant; 2008 May; 41(9):785-90. PubMed ID: 18176610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation.
    Ringdén O; Remberger M; Lehmann S; Hentschke P; Mattsson J; Klaesson S; Aschan J
    Bone Marrow Transplant; 2000 May; 25(9):993-6. PubMed ID: 10800069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.
    Sjöö F; Aschan J; Barkholt L; Hassan Z; Ringdén O; Hassan M
    Bone Marrow Transplant; 2003 Aug; 32(4):349-54. PubMed ID: 12900770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
    Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
    Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation.
    Pihusch M; Wegner H; Goehring P; Salat C; Pihusch V; Andreesen R; Kolb HJ; Holler E; Pihusch R
    Bone Marrow Transplant; 2005 Oct; 36(7):631-7. PubMed ID: 16062176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
    Dong M; Lin Q; Wu XY
    Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.
    Cheuk DK; Wang P; Lee TL; Chiang AK; Ha SY; Lau YL; Chan GC
    Bone Marrow Transplant; 2007 Nov; 40(10):935-44. PubMed ID: 17768390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of radio-labeled N-Acetyl-L-Cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage.
    Arfsten DP; Johnson EW; Wilfong ER; Jung AE; Bobb AJ
    Cutan Ocul Toxicol; 2007; 26(2):113-34. PubMed ID: 17612979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
    Tanikawa S; Mori S; Ohhashi K; Akiyama H; Sasaki T; Kaku H; Hiruma K; Matsunaga T; Morita T; Sakamaki H
    Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
    Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD).
    Kulkarni S; Rodriguez M; Lafuente A; Mateos P; Mehta J; Singhal S; Saso R; Tait D; Treleaven JG; Powles RL
    Bone Marrow Transplant; 1999 Apr; 23(8):803-7. PubMed ID: 10231143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone.
    Al Beihany A; Al Omar H; Sahovic E; Chaudhri N; Al Mohareb F; Al Sharif F; Al Zahrani H; Al Shanqeeti A; Seth P; Zaidi S; Morshed M; Al Anazi K; Mohamed G; Gyger M; Aljurf M
    Bone Marrow Transplant; 2008 Feb; 41(3):287-91. PubMed ID: 17982501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of intravenous N-acetylcysteine for acetaminophen overdose: analysis of the Hunter Area Toxicology Service (HATS) database.
    Whyte IM; Francis B; Dawson AH
    Curr Med Res Opin; 2007 Oct; 23(10):2359-68. PubMed ID: 17705945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Mori T; Aisa Y; Shimizu T; Yamazaki R; Mihara A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Am J Hematol; 2007 Sep; 82(9):838-9. PubMed ID: 17506069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
    Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
    Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal liver enzymes two years after haematopoietic stem cell transplantation in children: prevalence and risk factors.
    Bresters D; Van Gils IC; Dekker FW; Lankester AC; Bredius RG; Schweizer JJ
    Bone Marrow Transplant; 2008 Jan; 41(1):27-31. PubMed ID: 17994124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of low-dose heparin and prostaglandin E1 in the prevention of hepatic veno-occlusive disease after allogenic hematopoietic stem cell transplantation in children with beta-thalassemia major].
    Sun X; Hao WG; Liu S; Xia T; Liao C
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug; 9(4):343-6. PubMed ID: 17706036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.